Literature DB >> 11686103

Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.

C Mazurier1, J Goudemand, L Hilbert, C Caron, E Fressinaud, D Meyer.   

Abstract

Type 2N von Willebrand disease encompasses all patients with factor VIII deficiency caused by a markedly decreased affinity of von Willebrand factor for factor VIII. It is recessively inherited and clinically similar to mild haemophilia. The differential biological diagnosis is of major importance for providing the optimal treatment and relevant genetic counselling. This accurate diagnosis is based on an evaluation of the factor VIII-binding capacity of plasma von Willebrand factor. Furthermore, molecular biology techniques allow the identification of missense mutations in the von Willebrand factor gene. All of these induce the substitution of amino acid residues located in the N terminal part of the mature von Willebrand factor molecule, which contains the factor VIII binding site. Most of them induce a classical type 2N von Willebrand disease phenotype with factor VIII deficiency but a normal level and multimeric pattern of von Willebrand factor.

Entities:  

Mesh:

Year:  2001        PMID: 11686103     DOI: 10.1053/beha.2001.0138

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  16 in total

1.  Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis.

Authors:  Nicholas L Smith; Kenneth M Rice; Edwin G Bovill; Mary Cushman; Joshua C Bis; Barbara McKnight; Thomas Lumley; Nicole L Glazer; Astrid van Hylckama Vlieg; Weihong Tang; Abbas Dehghan; David P Strachan; Christopher J O'Donnell; Jerome I Rotter; Susan R Heckbert; Bruce M Psaty; Frits R Rosendaal
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

2.  Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Authors:  Augusto B Federici; Maria T Canciani
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

3.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

Review 4.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

5.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 6.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 7.  Current controversies in the diagnosis and management of von Willebrand disease.

Authors:  Anne T Neff
Journal:  Ther Adv Hematol       Date:  2015-08

8.  Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.

Authors:  Yuto Nakajima; Keiji Nogami; Koji Yada; Takeshi Kawamura; Kenichi Ogiwara; Shoko Furukawa; Naruto Shimonishi; Masahiro Takeyama; Midori Shima
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

Review 9.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

Review 10.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.